Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010117860) MICRORNA SIGNATURE TO PREDICT PROGNOSIS IN HEART FAILURE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/117860 International Application No.: PCT/US2010/029446
Publication Date: 14.10.2010 International Filing Date: 31.03.2010
IPC:
C12Q 1/68 (2006.01) ,C12N 15/11 (2006.01) ,A61K 31/7105 (2006.01) ,A61P 9/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
7105
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
Applicants:
KHAKOO, Aarif [US/US]; US (UsOnly)
CHAMPION, Hunter [US/US]; US (UsOnly)
CHINTALGATTU, Vishnu [IN/US]; US (UsOnly)
CALIN, George [RO/US]; US (UsOnly)
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th St. Austin, TX 78701, US (AllExceptUS)
THE JOHNS HOPKINS UNIVERSITY [US/US]; 3400 N. Charles Street Baltimore, MD 21218, US (AllExceptUS)
Inventors:
KHAKOO, Aarif; US
CHAMPION, Hunter; US
CHINTALGATTU, Vishnu; US
CALIN, George; US
Agent:
PARKER, David, L.; Fulbright & Jaworski LLP 600 Congress Ave., Suite 2400 Austin, TX 78701, US
Priority Data:
61/167,02806.04.2009US
Title (EN) MICRORNA SIGNATURE TO PREDICT PROGNOSIS IN HEART FAILURE
(FR) SIGNATURE DE MICRO-ARN UTILISÉE POUR LE PRONOSTIC DE L'INSUFFISANCE CARDIAQUE
Abstract:
(EN) Disclosed are methods and kits for determining prognosis of a subject with left ventricular dysfunction that involve determining expression level of one or more micro RNA ("miRNA") species selected from the group consisting of hsa-miR-367, hsa-miR- 10a, hsa-miR-187, hsa-miR-452, hsa-miR-218, hsa-miR-lOb, hsa-miR-214, hsa-miR- 193a, and hsa-miR-565 in a sample from the subject and comparing the expression level to a reference level. Also disclosed are methods and compositions for treating left ventricular dysfunction that include an inhibitor of CMPXl.
(FR) Cette invention concerne des méthodes et des kits de détermination d'un pronostic chez un sujet ayant un dysfonctionnement du ventricule gauche, qui impliquent de déterminer le taux d'expression d'un ou plusieurs micro-ARN ( » miRNA ») choisis dans le groupe constitué par hsa-miR-367, hsa-miR-10a, hsa-miR-187, hsa-miR-452, hsa-miR-218, hsa-miR-l0b, hsa-miR-214, hsa-miR- 193a et hsa-miR-565 dans un échantillon prélevé chez le sujet et de comparer le taux d'expression par rapport à un taux de référence. L'invention concerne des méthodes et des compositions permettant de traiter le dysfonctionnement du ventricule gauche et qui incluent un inhibiteur du gène CMPXl.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)